磷酸化蛋白质组学在三阴性乳腺癌诊治研究中的进展  

Phosphoproteomics in the diagnosis and treatment of triple-negative breast cancer:a review

作　　者：史云蔚 左涛 徐平 SHI Yunwei;ZUO Tao;XU Ping(Program of Environmental Toxicology,School of Public Health,China Medical University,Shenyang 110122,Liaoning,China;State Key Laboratory of Proteomics,Beijing Proteome Research Center,National Center for Protein Sciences(Beijing),Beijing Institute of Lifeomics,Academy of Military Medical Sciences,Academy of Military Sciences,Beijing 102206,China;Research Unit of Proteomics&Research and Development of New Drug,Chinese Academy of Medical Sciences,Beijing 102206,China)

机构地区：[1]中国医科大学公共卫生学院环境毒理学研究室,辽宁沈阳110122 [2]军事科学院军事医学研究院生命组学研究所国家蛋白质科学中心(北京)北京蛋白质组研究中心蛋白质组学国家重点实验室,北京102206 [3]中国医学科学院蛋白组学与新药研发创新单元,北京102206

出　　处：《生物工程学报》2024年第2期321-336,共16页Chinese Journal of Biotechnology

基　　金：国家自然科学基金(32101190,32070668,32141003);蛋白质组学国家重点实验室基金项目(2021-NCPSB-001,SKLP-C202002,SKLP-Y201901)。

摘　　要：三阴性乳腺癌是乳腺癌中恶性程度最高的亚型,其治疗仍以化疗为主,但容易出现耐药,且患者预后较差。随着蛋白质组学技术的发展,磷酸化蛋白质组学研究取得了长足的进步,并在肿瘤发生发展机制和诊治研究中得到了广泛的应用。同样,磷酸化蛋白质组学在三阴性乳腺癌的发生发展、靶向治疗和耐药机制研究等方面也发挥着重要作用。本文主要对目前磷酸化蛋白质组学在三阴性乳腺癌中的研究进展进行综述,旨在为基于磷酸化蛋白质组学的三阴性乳腺癌发生发展机制和诊治研究提供指导和帮助。Triple-negative breast cancer(TNBC)is the most malignant subtype of breast cancer.Currently,chemotherapy remains to be the primary treatment for TNBC,but drug resistance is common while patient prognosis is poor.With the development of proteomics technology,phosphoproteomics research has made great progress and has been widely used in the study of tumor mechanism,diagnosis and treatment.Similarly,phosphoproteomics plays a significant role in the studies of the occurrence,development,targeted therapy,and drug resistance mechanisms of TNBC.This article summarizes the research progress of phosphoproteomics in TNBC,with the aim to facilitate the research on the mechanism and treatment of TNBC based on phosphoproteomics.

关 键 词：蛋白质组学 磷酸化蛋白质组学 三阴性乳腺癌 

分 类 号：R737.9[医药卫生—肿瘤]